NHSBT/MRC Clinical Studies Unit
Platelets for Neonatal Transfusion Study 2 (PlaNeT-2):
Training UpdateA randomised controlled trial of platelet
transfusion thresholds
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
Neonatal Thrombocytopenia
• Prevalence: 1 - 5% of all newborns
• 25% NICU admissions
• 5-10% severe thrombocytopenia
NHSBT Clinical Trials UnitNHSBT CTU
NHSBT/MRC Clinical Studies Unit
RCT; n= 152• <1500g; GA < 33weeks; Platelet count
– Arm 1: Plt Tx to keep platelet count >150x109/L– Arm 2: Plt Tx at threshold count 50-150x109/L
No evidence ‘aggressive’ prophylaxis influenced incidence or extension of IVH
Andrew et al (1993)
Neonatal Thrombocytopenia: Current Evidence (I)
NHSBT Clinical Trials UnitNHSBT CTU
NHSBT/MRC Clinical Studies Unit
No increased haemorrhage irrespective of whether platelets were administered
Murray et al (2002)
G iv enp la te le t tra ns fu sio ns
1 5 /17 (88 % )
N o t g ivenp la te le t tra ns fu sio ns
2 /1 7 (1 2 % )
P la te le t c o un t na d ir < 301 7 /44 (39 % )
G iv enp la te le t tra ns fu sio ns
1 0 /27 (37 % )
N o t g iv enp la te le t tra ns fu sio ns
1 7 /27 (63 % )
P la te le t cou n t n a d ir 30 -502 7 /44 (61 % )
P re te rm ne o na tes4 44 4
Neonatal Thrombocytopenia: Current Evidence (II)
NHSBT Clinical Trials UnitNHSBT CTU
NHSBT/MRC Clinical Studies Unit
Retrospective Cohort Analysis of neonates with NEC and platelets <100x109/L
• Results suggested platelet transfusions in infants with NEC associated with greater morbidity
Kenton et al (2005)
Neonatal Thrombocytopenia: Current Evidence (III)
NHSBT Clinical Trials UnitNHSBT CTU
NHSBT/MRC Clinical Studies Unit
Baer et al (2007)
Neonatal Thrombocytopenia: Current Evidence (IV)
NHSBT Clinical Trials UnitNHSBT CTU
NHSBT/MRC Clinical Studies Unit
Current national transfusion guidance based on consensus rather than evidence
British Committee for Standards in Haematology (2004) United Kingdom Blood Services (2007)
Survey in the UK showed wide variation in platelet transfusion practice
Chaudhary and Clarke (2008)
Neonatal Thrombocytopenia: Current Practice
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
PlaNeT-1: A Study of Outcomes
• Prospective observational study of NICU admissions with platelet counts <60x109/L
• 7 NICUs• 169 neonates studied for 7 days, or until platelets >60x109/L
– Platelet count– Haemorrhage– Platelet transfusions– Outcome
Stanworth et al (2009)
NHSBT Clinical Trials UnitNHSBT Clinical Trials UnitNHSBT Clinical Trials UnitNHSBT CTU
NHSBT/MRC Clinical Studies Unit
PlaNeT-1: Haemorrhage
NHSBT Clinical Trials UnitNHSBT CTU
NHSBT/MRC Clinical Studies Unit(++) indicates group median and (- -) IQR
PlaNeT-1: Lowest Platelet Counts
NHSBT CTU (++) indicates group median and (- -) IQR
NHSBT/MRC Clinical Studies Unit
PlaNeT-1: Transfusions
• 2/3 received platelet transfusion
• Most transfusions given as prophylaxis often well after “risk period” for haemorrhage has passed
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
Moving forward!
NHSBT Clinical Trials UnitNHSBT CTU
NHSBT/MRC Clinical Studies Unit
Platelets for Neonatal Transfusion - Study 2
PlaNeT-2
NHSBT Clinical Trials UnitNHSBT CTU
NHSBT/MRC Clinical Studies Unit
PlaNeT-2: Study design (I)
Two-stage, randomised, parallel group, superiority trial.
Aim: to compare two different platelet count thresholds for prophylactic platelet transfusion to preterm neonates.
Primary Outcome:• Proportion of patients who either die or experience a major
bleed up to and including study day 28.
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
PlaNeT-2: Study design (II)
Secondary Outcomes:• Proportion of neonates surviving to home following a
major bleed• Mortality prior to day 28• Major bleeds by day 28 • Platelets transfused to study day 28• Length of hospital stay• Transfusion-related adverse events • Neuro-developmental outcome
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
PlaNeT-2: Platelet thresholds
• Arm A Standard: transfuse platelets at <25x109/L (330 neonates)
• Arm B Intervention: transfuse platelets at <50x109/L(330 neonates)
• Dose: 15 ml/kg
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
PlaNeT-2: Additional platelet transfusionsMay be considered under the following circumstances:
• Therapeutically to treat major bleeding, following objective and documented signs of clinically relevant bleeding graded as moderate, major or severe, but not for minor bleeding.
• Prior to planned invasive procedures as below only – Suprapubic aspiration – Lumbar puncture – Major surgery where haemostasis may be critical to outcome.
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
Grade 1 – Minor HaemorrhageAny bleed from the
· skin, umbilical cord, skin around stoma, surgical scar, mucosa.· Any pink frothy or old bleed from the ET tube. · H1 haemorrhage on cranial US (Germinal Layer Haemorrhage, GLH)
Grade 2 – Moderate HaemorrhageAny frank bleed from
• the stoma • macroscopic haematuria, • IVH (H2 or H3) without dilatation (V0), • Acute fresh bleed through ETT without ventilatory changes
Grade 3 – Major Haemorrhage any:• Frank Rectal • Acute fresh bleed through ETT with ventilatory change. • Intracranial bleed An intracranial bleed is defined as a major bleed if any of the following apply: Neurosurgical
intervention is required; Scans show a midline shift; Clinical signs and symptoms of neurolgical deficit with significant derangement of laboratory investigations
• Major IVH is defined as H2 or H3 with ventricular dilatation (V1); H1, H2, H3 with parenchymal involvement (P3) ; Any evolution of intracranial haemorrhage to H2V1, H3V1, or (H1, H2, H3) with parenchymal involvement (P3)
Grade 4 – Severe Haemorrhage• Shock defined as life threatening major bleed associated with hypotension, hyopovolaemia or any other
haemodynamic instability and/or bleeding requiring volume boluses, red cell transfusion in the same 24 hours, fatal major bleeding
Modified WHO Bleeding Assessment Score
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
• Admission to a participating NICU (includes postnatal transfers)
• <34 weeks GA at birth
• Platelet count of <50 x109/L
• Cranial ultrasound scan: undertaken <6 hours before randomisation to exclude recent major IVH
PlaNeT-2: Inclusion criteria
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
• Major/life-threatening congenital malformations
• Recent major haemorrhage within the last 72 hours
• All fetal intracranial haemorrhages
• Known immune thrombocytopenia
• Neonates unlikely to survive
• Neonates not given parenteral vitamin K
PlaNeT-2: Exclusion criteria
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
When platelets <100x109/L
Parents will be
counselled
Written, informed
consent will be obtained
Documented in the clinical
notes
Three copies signed:• For parents• For the clinical
notes with Parent Information Sheet
• For the study file
When platelets <50x109/L
Parents will be approached for consideration of immediate
study participation.
PlaNeT-2: Consent
Document on PlaNeT-2 log book
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
PlaNeT-2: Randomisation
When the consent is signed and platelets <50x109/L:
Pre-randomisation
Platelet transfusion information
(FA)
Pre-randomisation
form (F1)
Eligibility for randomisation
(F2)
Current medical
conditions & previous major
bleeds (F3)
Randomisation (F4)
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
FA – Platelet transfusion information
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
F1 – Pre-randomisation
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
F2 – Eligibility for randomisation
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
F3 – Current medical conditionsAnd previous major bleeds
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
SD1
BAT
SD2
BAT
SD3
BAT
SD4
BAT
SD5
BAT
SD6
BAT
SD7
BATUSS
SD8
BAT
SD9
BAT
SD10
BAT
SD11
BAT
SD12
BAT
SD13
BAT
SD14
BAT
USS
SD15
BAT
SD16
BAT
SD17
BAT
SD18
BAT
SD19
BAT
SD20
BAT
SD21
BATUSS
SD22
BAT
SD23
BAT
SD24
BAT
SD25
BAT
SD26
BAT
SD27
BAT
SD28
BAT
USS
SD29 SD30 SD31 SD32 SD33 SD34
SD35
Weekly
SD36 SD37 … … … …
END
USS
PlaNeT-2: Data collection (I)
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
F5 – Bleeding Assessment Tool (BAT)
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
F7 – Weekly Data Collection
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
Platelet Transfusion Data (F8)
Necrotising enterocolitis (NEC) /Sepsis Form (F9)
Discontinuation of Treatment Allocation (F10)
Major/Severe Bleed (F13)
Serious Adverse Event (F14)
Serious Platelet Transfusion Related Adverse Event (F15)
PlaNeT-2: Data collection (II)
F9
F13
F10
F14
F15
F8
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
F8 – Platelet Transfusion Data
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
• Necrotising enterocolitis ≥ Stage 2 defined as per Bells Criteria (Bell et al,1978)
• Sepsis: culture positive sepsis or culture negative sepsis where a course of at least 5 days of antibiotics is to be administered for proven or clinically-suspected sepsis.
• All episodes of NEC and sepsis must be recorded on the adverse event form
• A listing of adverse events will be reported six monthly to the Independent Data Monitoring Committee.
PlaNeT-2: NEC/Sepsis form
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
F9 – NEC/Sepsis form
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
F10 – Discontinuation of Treatment Allocation
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
• All new major bleeding events will be reported to the CSU without disclosing allocation arm.
• Each report will be forwarded to the Independent Data Monitoring Committee for review as soon as it is received at the CSU.
• In cases of uncertainty the local team may contact one of the CIs or neonatal medical experts.
MAJOR BLEED FORMWithin one working day of becoming aware of an Major Bleed, please fax a completed Major Bleed form to the NHSBT/MRC
CSUFax: 01223 588136
PlaNeT-2: Major/Severe bleed form
NHSBT/MRC Clinical Studies Unit
F13 – Major/Severe Bleed
NHSBT CTU
NHSBT/MRC Clinical Studies UnitSAE NOTIFICATION
Within one working day of becoming aware of an SAE, please fax a completed SAE form to the NHSBT/MRC CSU
Fax: 01223 588136
• in death• is life-threatening • requires hospitalisation or prolongation of existing
hospitalisation (including readmission within 28 study days if discharged home earlier)
• there is a likelihood of persistent or significant disability or incapacity
A SAE is an adverse event that results:
PlaNeT-2: Serious Adverse Event (SAE)
NHSBT/MRC Clinical Studies Unit
F14 – Serious Adverse Event
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
Data collected on serious transfusion related adverse reactions/events will be based on current definitions used by hospitals reporting to UK national haemovigilance reporting schemes (SHOT and MHRA).
These definitions cover the following: Incorrect blood component transfused Acute transfusion reactions Transfusion Related Acute Lung Injury (TRALI) Transfusion transmitted infections, including bacterial transmission Transfusion Associated Circulatory Overload (TACO)
PlaNeT-2: Serious platelet transfusion related adverse event
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
F15 – Serious platelet transfusion related adverse event
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
PlaNeT-2: End of study
Data collection will cease when the baby is 38 weeks corrected gestational age or time of discharge home
Cranial Ultrasound at End of Study (F11)
End of Study (F12)
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
F11 – Cranial USS at the end of study
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
F12 – End of study
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
• Inform the local PlaNeT-2 team if neonate transferred out of recruiting unit
• Keep all the forms, do not send them with the patient
• Receiving hospital should:• Collect information as required by the protocol thereafter until 38 weeks
CGA or discharge. • Continue to give any required platelet transfusions according to the
randomised platelet threshold.
PlaNeT-2: Transfer out of recruiting unit
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
• Black ink
• For platelet count use the date and time the sample is received in the lab
• Do not leave blank fields, enter leading zeros
• Any data incorrectly recorded must be crossed through with a single line and the correct value documented by the side. All corrections must be initialled and dated by the individual making the changes
PlaNeT-2: Data Quality
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
• Ethics approval obtained from the regional ethics committee
• NIHR adopted
• CLRN adopted
PlaNeT-2: Research & Development and Ethics approval
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
PlaNeT-2: Trial Governance
The Trial Management Group (TMG) will be responsible for the daily management of the trial.
The TMG is responsible to the Trial Steering Committee which has oversight of the trial and provides advice as needed
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
PlaNeT-2: TMG Group
• Louise Choo• Paul Clarke• Anna Curley• Alison Deary• Rizwan Khan• Renate Hodge
• Priya Muthukumar• Helen New• Simon Stanworth• Vidheya Venkatesh• Tim Watts• Karen Willoughby
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
PlaNeT-2: Finance
The trial is funded by a Project Grant from the NHSBT which is administered by the National Research & Development Committee.
Any payments will be made to participating centres to cover costs associated with the undertaking of this trial, as specified in Individual Investigator Site Agreements.
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
• For general trial queries: contact • Karen Willoughby [email protected], copy to
• For medical queries regarding transfusions, SAEs, grading major/severe bleeds or transfusion reactions contact
• Simon Stanworth: [email protected], or • Anna Curley: [email protected]
PlaNeT-2: Communications
www.planet-2.com
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
References• Andrew M, Vegh P, Caco C, Kirpalani H, Jeffries A, Ohlsson A, Watts J, Sagial S, Milner R, Wang EA. (1993) Randomised
controlled trial of platelet transfusions in thrombocytopenic premature infants. Journal of Pediatrics 123 285–291. • Baer VL, Lambert DK, Henry E, Snow GL, Sola-Visner MC, Christensen RD (2007) Do platelet transfusions in the NICU
adversely affect survival? Analysis of 1600 thrombocytopenic neonates in a multihospital healthcare systemMultiple platelet transfusions and survival. Journal of Perinatology 27 790-796.
• British Committee for Standards in Haematology (2004) Transfusion Guidelines for neonates and older children. British Journal of Haematology 124 433-453.
• Chaudhary R, Clarke P. (2008) Current transfusion practices for platelets and fresh, frozen plasma in UK tertiary level neonatal units. Acta Pædiatrica 97(1) 135.
• Kenton AB, Hegemier S, Smith EO, O'Donovan DJ, Brandt ML, Cass DL, Helmrath MA, Washburn K, Weihe EK, Fernandes CJ (2005) Platelet transfusions in infants with necrotizing enterocolitis do not lower mortality but may increase morbidity. Journay of Perinatology 25(3) 173–177
• Murray NA, Howarth LJ, McCloy MP, Letsky EA, Roberts IAG (2002) Platelet transfusion in the management of severe thrombocytopenia in neonatal intensive care unit patients. Transfusion Medicine 12(1) 35-41.
• Stanworth S, Clarke P, Watts T, Ballard S, Choo L, Morris T, Murphy MF, Roberts I (2009) Prospective, observational study of outcomes in neonates with severe thrombocytopenia. Pediatrics 124 826-834.
• United Kingdom Blood Services (2007) Handbook of Transfusion Medicine. 4th ed. Norwich: The Stationary Office. [online]. Available from: http://www.transfusionguidelines.org.uk/index.aspx?Publication=HTM
NHSBT CTU
NHSBT/MRC Clinical Studies Unit
Thank you!
NHSBT CTU